Fycompa is an oral medication and is the first FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor antagonist. Perampanel CIII was approved by the FDA in October 2012 and
The two firms have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds. As part of the deal, NewLink will receive $150m in
The US-based company has also agreed to carry out human clinical trials using its HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1) in the region. With
The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis. Novartis
The company is focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3
Hyqvia consists of Immune Globulin Infusion 10% (Human) (IG 10%) and recombinant human hyaluronidase developed by Halozyme. The immune globulin treatment for PI in adults was approved by
If approved, it would be the first pediatric combination vaccine in the US designed to help protect against six important diseases including diphtheria, tetanus, pertussis (whooping cough), polio
The US Food and Drug Administration (FDA) has approved Contrave as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with
In 2011, MedImmune licensed the OX40 agonist platform from AgonOx as a result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the
The company said that the drug candidate in the ALS trial is called as GM604 and GM608 in the PD trial. For the treatment of ALS, the company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.